Status:

TERMINATED

ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.

Lead Sponsor:

Dijklander Ziekenhuis

Collaborating Sponsors:

ZonMw: The Netherlands Organisation for Health Research and Development

Amsterdam UMC, location VUmc

Conditions:

Abdominal Aortic Aneurysm

Surgery

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Aim of the ACTION-1 study is to determine whether ACT guided heparinization decreases thrombo-embolic complications (TEC) and mortality after elective open AAA surgery, without causing more bleeding c...

Detailed Description

Heparin is used during open abdominal aortic aneurysm (AAA) surgery to reduce thrombo-embolic complications (TEC): such as myocardial infarction, stroke, peripheral embolic events and the related mort...

Eligibility Criteria

Inclusion

  • Able to speak and read in local language of trial hospital.
  • Patients older than 18 years scheduled for elective, open repair of an iliac or abdominal aortic aneurysm distal of the Superior Mesenteric Artery (SMA) (DSAA segment C).
  • Implantation of a tube or bifurcation prosthesis.
  • Trans-abdominal or retroperitoneal surgical approach of aneurysm.
  • Able and willing to provide written informed consent.

Exclusion

  • Not able to provide written informed consent.
  • Previous open or endovascular intervention on the abdominal aorta (previous surgery on other parts of the aorta or iliac arteries is not an exclusion criterion).
  • History of coagulation disorders, heparin induced thrombocytopenia (HIT), allergy for heparin or thrombocyte pathology.
  • Impaired renal function with EGFR below 30 ml/min.
  • Acute open AAA surgery.
  • Hybrid interventions.
  • Connective tissue disorders.
  • Dual anti-platelet therapy, which cannot be discontinued.
  • Life expectancy less than 2 years.
  • Inflammatory, mycotic or infected aneurysms.
  • Allergy for protamine or fish protein

Key Trial Info

Start Date :

March 2 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 29 2024

Estimated Enrollment :

294 Patients enrolled

Trial Details

Trial ID

NCT04061798

Start Date

March 2 2020

End Date

April 29 2024

Last Update

February 6 2025

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany

2

Krankenhaus Barmherzige Brüder

Regensburg, Germany

3

Treant Zorggroep

Emmen, Drenthe, Netherlands, 7824AA

4

Gelre Ziekenhuizen

Apeldoorn, Gelderland, Netherlands, 7334DZ